Drug Profile
Research programme: prophylactic DNA vaccines - Fresh Tracks Therapeutics/US Naval Medical Research Center
Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics; Naval Medical Research Center
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 19 Sep 2023 Discontinued for Infections (Prevention) in USA (unspecified route)
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary